Vice President, Head of Medical Safety, Marketed Products, Global Patient Safety Evaluation
Takeda
Laurel, United States
Dr. Hammad joined Takeda, early in 2022, as Vice President, Head of Medical Safety, Marketed Products Group and PV Policy Intelligence Strategy. Prior to this, he served as Therapeutic Area Strategy Lead in the Global Pharmacovigilance group in Sanofi and as the Head of Signal Detection and Benefit-Risk Assessment in Merck KGaA. Previously, he was an Executive Director of Pharmacoepidemiology in Merck. Dr. Hammad has had a long and distinguished career with the United States FDA for 13 years with increasing responsibilities, the latest position being the Deputy Division Director of Pharmacoepidemiology, CDER. He is a recipient, among many awards, of the FDA Distinguished Service Award and the Frances Kelsey Excellence in Drug Safety. Throughout his career, Dr. Hammad has made significant contributions to the scientific community through teaching, publications, as a peer reviewer for major scientific journals, and working with public-private consortia dedicated to advancing innovation in drug development (e.g., the Innovation in Medicine Initiative (IMI) and the Council for International Organizations of Medical Sciences (CIOMS)). Tarek additionally brings expertise demonstrated by his participation as PhRMA representative in the ICH Expert Working Group (EWG M4E(R2)) “Enhancing the Format and Structure of Benefit-Risk Information”. He is nationally and internationally recognized as drug safety, pharmacoepidemiology, and benefit-risk expert. Tarek is a frequent speaker, session chair, or program committee member at industry symposia and scientific conferences. He held several academic appointments and published more than 80 peer-reviewed articles, letters to the editor, and book chapters. For more information, check his professional website www.DrTarekHammad.com.
Disclosure information not submitted.
Wednesday, August 23, 2023
2:00 PM – 6:00 PM ADT
